title: Rosiglitazone increases myocardial glucose metabolism in insulin-resistant cardiomyopathy.
authors.forename: David P
authors.initials: DP
authors.lastname: Kao
authors.forename: Ronald M
authors.initials: RM
authors.lastname: Witteles
authors.forename: Andrew
authors.initials: A
authors.lastname: Quon
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Wu
authors.forename: Sanjiv Sam
authors.initials: SS
authors.lastname: Gambhir
authors.forename: Michael B
authors.initials: MB
authors.lastname: Fowler
mesh_terms: D000818:Animals; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000378:metabolism; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007333:Insulin Resistance; D009206:Myocardium / Q000378:metabolism*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*; D014665:Vasodilator Agents
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D014665:Vasodilator Agents; D000077154:Rosiglitazone; D005947:Glucose